SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVO.L Regulatory News (DVO)

  • There is currently no data for DVO

Trading Update

10 Nov 2016 07:00

RNS Number : 8050O
Devro PLC
10 November 2016
 

This announcement contains inside information

10 November 2016

 

Devro plc

 

Trading Update

 

Devro plc ("the Group"), one of the world's leading manufacturers of collagen products for the food industry, today issues a trading update for the period 1 July 2016 to the current date ("the period").

Trading summary for the period and 2016 outlook

Sales volume trends were broadly similar to those experienced in the first half, enhanced by improvements in Russia and South East Asia, but impacted by further reductions in Latin America due to the previously highlighted issues, which are being addressed, related to the transformation of our global manufacturing footprint. Combined, these factors have had an adverse impact on margins, offset by further benefits from lower input costs and foreign exchange. As a result, the Board's full year expectations for underlying operating profit* remain unchanged.

Our new factories in the US and China are now integrated into the Group's manufacturing base, completing the transformation of our global manufacturing footprint. As expected, in the second half £8 million of exceptional costs related to these capital investment projects have been incurred, including £1 million of additional foreign exchange movements. There will be no further exceptional costs related to these capital investment projects.

2017 and beyond

Based on current trends, sales volumes in 2017 are now expected to be approximately 10% lower than previously anticipated, which will result in an under-utilisation of available capacity. Actions are being taken to rebalance the use of capacity across our global manufacturing base. The under-utilisation is expected to have a further adverse impact on margins.

The Board has decided to accelerate and implement more extensively the next stage of the Group's strategic development, focusing on growing sales through improved commercial capabilities, introducing the next generation of differentiated products, and further improving manufacturing efficiencies to reduce unit costs. This improvement project will deliver a fundamentally more competitive position. The benefits will offset the effects of the lower volumes, partially in 2017 and fully in 2018. 

Consequently, the Board now expects underlying operating profit* for 2017 to be lower than previous expectations.

There will be additional costs and capital expenditure associated with the improvement project. Given the nature and scale of the planned actions, these costs will be charged as exceptional items, of which approximately £3 million is expected to be incurred in the final quarter of 2016.

Devro's markets remain attractive. With completion of the capital investment projects the Group now has an excellent manufacturing base and, with the benefits resulting from the improvement project, the Board considers the Group to be well positioned to grow revenue and profits over the long term.

* Underlying operating profit is defined as operating profit before exceptional items

 

ENDS

 

 

Contacts:

 

Devro plc

Peter Page

Chief Executive

Tel: 020 7182 4960

Rutger Helbing

Group Finance Director

Tel: 020 7182 4960

 

FTI Consulting

Richard Mountain / Nick Hasell

Tel: 020 3727 1340

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFSIEFUFMSEDF
Date   Source Headline
7th Apr 20204:00 pmRNS2019 Annual Report and Notice of AGM
31st Mar 202012:03 pmRNSPrice Monitoring Extension
26th Mar 20204:37 pmRNSPrice Monitoring Extension
17th Mar 20207:00 amRNSDirectorate Changes
9th Mar 20202:26 pmRNSHolding(s) in Company
6th Mar 20205:10 pmRNSDirector/PDMR Shareholding
6th Mar 202012:11 pmRNSDirector/PDMR Shareholding
6th Mar 202012:11 pmRNSDirector/PDMR Shareholding
4th Mar 20207:00 amRNSFull Year Results
17th Jan 20207:00 amRNSTrading Update
12th Dec 20198:42 amRNSDirector Declaration
25th Oct 20195:31 pmRNSDirector/PDMR Shareholding
24th Oct 201910:57 amRNSDirector/PDMR Shareholding
22nd Oct 20197:00 amRNSTrading Update & Manufacturing Footprint Review
10th Oct 201911:44 amRNSDirector/PDMR Shareholding
20th Sep 201912:59 pmRNSHolding(s) in Company
14th Aug 20191:45 pmRNSHolding(s) in Company
31st Jul 20197:00 amRNSHALF YEAR RESULTS
5th Jul 20191:17 pmRNSHolding(s) in Company
19th Jun 20197:00 amRNSHolding(s) in Company
15th May 20196:24 pmRNSDirector/PDMR Shareholding
14th May 20193:44 pmRNSDirector/PDMR Shareholding
7th May 20197:00 amRNSDirectorate Changes
2nd May 20193:28 pmRNSDirector/PDMR Shareholding
25th Apr 20194:04 pmRNSResult of AGM
25th Apr 20197:00 amRNSTrading Update
12th Apr 20191:08 pmRNSCompany Secretary change
11th Apr 201910:48 amRNSDirector/PDMR Shareholding
22nd Mar 20194:07 pmRNS2018 Annual Report and Notice of AGM
19th Mar 20192:00 pmRNSCapital Markets Event
6th Mar 20192:09 pmRNSDirector/PDMR Shareholding
6th Mar 20192:08 pmRNSDirector/PDMR Shareholding
26th Feb 20197:00 amRNSFull Year Results
20th Feb 20193:27 pmRNSHolding(s) in Company
14th Feb 201911:59 amRNSHolding(s) in Company
14th Feb 201911:34 amRNSDirector/PDMR Shareholding
23rd Jan 20193:02 pmRNSHolding(s) in Company
10th Dec 20184:05 pmRNSHolding(s) in Company
4th Dec 20184:46 pmRNSHolding(s) in Company
20th Nov 20183:33 pmRNSHolding(s) in Company
20th Nov 201811:51 amRNSHolding(s) in Company
19th Nov 20181:35 pmRNSDirector/PDMR Shareholding
19th Nov 20181:34 pmRNSDirector/PDMR Shareholding
16th Nov 201810:33 amRNSDirector/PDMR Shareholding
15th Nov 20187:00 amRNSRetirement of Chairman
15th Nov 20187:00 amRNSTrading Update
5th Nov 20181:49 pmRNSHolding(s) in Company
23rd Oct 20183:47 pmRNSHolding(s) in Company
15th Oct 20184:27 pmRNSDirector/PDMR Shareholding
18th Sep 201811:33 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.